Clarus Wealth Advisors purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 1,000 shares of the life sciences company’s stock, valued at approximately $304,000.
Other hedge funds have also made changes to their positions in the company. Next Capital Management LLC acquired a new position in shares of Illumina in the second quarter valued at approximately $25,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Illumina in the second quarter valued at approximately $37,000. North Star Investment Management Corp. acquired a new position in shares of Illumina in the third quarter valued at approximately $31,000. Trustcore Financial Services LLC acquired a new position in shares of Illumina in the second quarter valued at approximately $44,000. Finally, Focused Wealth Management Inc grew its holdings in shares of Illumina by 1,462.5% in the second quarter. Focused Wealth Management Inc now owns 125 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 117 shares in the last quarter. Hedge funds and other institutional investors own 90.90% of the company’s stock.
ILMN has been the subject of a number of research reports. Deutsche Bank dropped their price objective on shares of Illumina from $290.00 to $280.00 and set a “hold” rating for the company in a report on Friday, July 12th. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Friday, September 13th. UBS Group lifted their price objective on shares of Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. ValuEngine upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Thursday, September 12th. Finally, Canaccord Genuity cut shares of Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the company from $330.00 to $300.00 in a report on Tuesday, July 30th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the stock. Illumina has a consensus rating of “Buy” and an average price target of $330.92.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.32 by $0.03. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The company had revenue of $838.00 million during the quarter, compared to the consensus estimate of $835.12 million. During the same quarter in the previous year, the firm earned $1.43 earnings per share. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. As a group, research analysts anticipate that Illumina, Inc. will post 6.04 earnings per share for the current fiscal year.
In other news, SVP Oene Mark Van sold 625 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $304.84, for a total transaction of $190,525.00. Following the completion of the sale, the senior vice president now owns 14,209 shares in the company, valued at approximately $4,331,471.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Mostafa Ronaghi sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $302.04, for a total transaction of $3,020,400.00. Following the sale, the senior vice president now owns 86,776 shares of the company’s stock, valued at approximately $26,209,823.04. The disclosure for this sale can be found here. Insiders sold 47,099 shares of company stock valued at $13,897,460 in the last quarter. 0.38% of the stock is owned by insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Story: Understanding Specialty Certificates of Deposit
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.